PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.24%
Revenue growth above 1.5x AVGO's 0.59%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
47.23%
Gross profit growth above 1.5x AVGO's 0.51%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
83.58%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
83.58%
Positive operating income growth while AVGO is negative. John Neff might view this as a competitive edge in operations.
67.24%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
72.41%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
72.41%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
18.75%
Share count expansion well above AVGO's 0.26%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
18.75%
Slight or no buyback while AVGO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-13.45%
Dividend reduction while AVGO stands at 0.14%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-62.05%
Negative OCF growth while AVGO is at 7.23%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-67.65%
Negative FCF growth while AVGO is at 6.62%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-45.13%
Negative 10Y revenue/share CAGR while AVGO stands at 409.54%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-35.18%
Negative 5Y CAGR while AVGO stands at 122.61%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-24.61%
Negative 3Y CAGR while AVGO stands at 60.90%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
1782.46%
10Y OCF/share CAGR above 1.5x AVGO's 441.92%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-18.33%
Negative 5Y OCF/share CAGR while AVGO is at 73.80%. Joel Greenblatt would question the firm’s operational model or cost structure.
14.77%
3Y OCF/share CAGR under 50% of AVGO's 34.25%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-148.33%
Negative 10Y net income/share CAGR while AVGO is at 691.11%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-123.65%
Negative 5Y net income/share CAGR while AVGO is 651.30%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-112.54%
Negative 3Y CAGR while AVGO is 66.58%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
216.59%
Below 50% of AVGO's 839.21%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
124.69%
5Y equity/share CAGR at 75-90% of AVGO's 147.32%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
49.26%
Below 50% of AVGO's 188.08%. Michael Burry suspects a serious short-term disadvantage in building book value.
-27.60%
Cut dividends over 10 years while AVGO stands at 1441.93%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-7.16%
Negative 5Y dividend/share CAGR while AVGO stands at 71.80%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-5.66%
Negative near-term dividend growth while AVGO invests at 38.29%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
4.26%
AR growth is negative/stable vs. AVGO's 14.59%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
2.26%
Inventory shrinking or stable vs. AVGO's 5.71%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
-1.53%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-16.01%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
0.24%
Debt shrinking faster vs. AVGO's 1.06%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
1.57%
R&D dropping or stable vs. AVGO's 19.53%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-11.96%
We cut SG&A while AVGO invests at 14.12%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.